San Francisco Bay Area biotech stories.
Thursday, September 27, 2012
Onyx, Bayer win approval of colorectal cancer drug regorafenib
Onyx CEO Tony Coles.
Bayer HealthCare and Onyx Pharmaceuticals Inc. won approval Thursday of their colorectal cancer drug regorafenib.
The Food and Drug Administration's speedy approval -- regorafenib was submitted for approval in colorectal cancer in April and
submitted for approval for gastrointestinal stromal tumors at the end of August
-- follows South San Francisco-based Onyx's approval in July of its treatment for multiple myeloma, called Kyprolis. Regorafenib will be marketed as Stivarga.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)